CORDIS - Resultados de investigaciones de la UE
CORDIS

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions

Descripción del proyecto

Identificar los motivos de la respuesta negativa de los pacientes al tratamiento

La identificación de los mecanismos moleculares que pueden influir de manera positiva o negativa sobre la respuesta de un paciente a un tratamiento médico es una cuestión de vital importancia para los profesionales de la salud. Un estudio promovido por 3TR, un consorcio de instituciones universitarias, pymes y empresas farmacéuticas líderes, abordará esta cuestión. Este proyecto financiado con fondos europeos aplicará métodos bioinformáticos y de control para recopilar y analizar datos de la sangre, los tejidos y otros fluidos a lo largo de todo el proceso de tratamiento. Creará una plataforma centralizada de datos para mejorar la gestión y aplicará una imagen clínica y molecular integradora de pacientes que sufran enfermedades similares. El proyecto tiene como finalidad explicar el papel que desempeñan durante el tratamiento nuestro microbioma, la genética y la genómica reguladora.

Objetivo

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.
Aportación neta de la UEn
€ 9 468 779,68
Dirección
AVENIDA AMERICO VESPUCIO 15 EDIF S2
41092 Sevilla
España

Ver en el mapa

Región
Sur Andalucía Sevilla
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 9 579 779,68

Participantes (86)